Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.

Hdl Handle:
http://hdl.handle.net/10147/209195
Title:
Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
Authors:
Minihan, M; Goggin, M; Cleary, P E
Affiliation:
Department of Ophthalmology, Cork University Hospital, Wilton, Ireland.
Citation:
Br J Ophthalmol. 1997 Dec;81(12):1073-9.
Journal:
The British journal of ophthalmology
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/209195
PubMed ID:
9497468
Abstract:
BACKGROUND: Vitrectomy and gas tamponade has become a recognised technique for the treatment of macular holes. In an attempt to improve the anatomic and visual success of the procedure, various adjunctive therapies--cytokines, serum, and platelets--have been employed. A consecutive series of 85 eyes which underwent macular hole surgery using gas tamponade alone, or gas tamponade with either the cytokine transforming growth factor beta 2 (TGF-beta 2) or autologous platelet concentrate is reported. METHODS: Twenty eyes had vitrectomy and 20% SF6 gas tamponade; 15 had vitrectomy, 20% SF6 gas, and TGF-beta 2; 50 had vitrectomy, 16% C3F8 gas tamponade, and 0.1 ml of autologous platelet concentrate prepared during the procedure. RESULTS: Anatomic success occurred in 86% of eyes, with 96% of the platelet treated group achieving closure of the macular hole. Visual acuity improved by two lines or more in 65% of the SF6 only group, 33% of those treated with TGF-beta 2 and in 74% of the platelet treated group. In the platelet treated group 40% achieved 6/12 or better and 62% achieved 6/18 or better. The best visual results were obtained in stage 2 holes. CONCLUSION: Vitrectomy for macular holes is often of benefit and patients may recover good visual acuity, especially early in the disease process. The procedure has a number of serious complications, and the postoperative posturing requirement is difficult. Patients need to be informed of such concerns before surgery.
Language:
eng
MeSH:
Adult; Aged; Aged, 80 and over; Blood Transfusion, Autologous; Combined Modality Therapy; Female; Gases/*therapeutic use; Humans; Male; Middle Aged; *Platelet Transfusion; Postoperative Period; Prospective Studies; Retinal Perforations/surgery/*therapy; Transforming Growth Factor beta/*therapeutic use; Visual Acuity; *Vitrectomy
ISSN:
0007-1161 (Print); 0007-1161 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMinihan, Men_GB
dc.contributor.authorGoggin, Men_GB
dc.contributor.authorCleary, P Een_GB
dc.date.accessioned2012-02-03T15:14:46Z-
dc.date.available2012-02-03T15:14:46Z-
dc.date.issued2012-02-03T15:14:46Z-
dc.identifier.citationBr J Ophthalmol. 1997 Dec;81(12):1073-9.en_GB
dc.identifier.issn0007-1161 (Print)en_GB
dc.identifier.issn0007-1161 (Linking)en_GB
dc.identifier.pmid9497468en_GB
dc.identifier.urihttp://hdl.handle.net/10147/209195-
dc.description.abstractBACKGROUND: Vitrectomy and gas tamponade has become a recognised technique for the treatment of macular holes. In an attempt to improve the anatomic and visual success of the procedure, various adjunctive therapies--cytokines, serum, and platelets--have been employed. A consecutive series of 85 eyes which underwent macular hole surgery using gas tamponade alone, or gas tamponade with either the cytokine transforming growth factor beta 2 (TGF-beta 2) or autologous platelet concentrate is reported. METHODS: Twenty eyes had vitrectomy and 20% SF6 gas tamponade; 15 had vitrectomy, 20% SF6 gas, and TGF-beta 2; 50 had vitrectomy, 16% C3F8 gas tamponade, and 0.1 ml of autologous platelet concentrate prepared during the procedure. RESULTS: Anatomic success occurred in 86% of eyes, with 96% of the platelet treated group achieving closure of the macular hole. Visual acuity improved by two lines or more in 65% of the SF6 only group, 33% of those treated with TGF-beta 2 and in 74% of the platelet treated group. In the platelet treated group 40% achieved 6/12 or better and 62% achieved 6/18 or better. The best visual results were obtained in stage 2 holes. CONCLUSION: Vitrectomy for macular holes is often of benefit and patients may recover good visual acuity, especially early in the disease process. The procedure has a number of serious complications, and the postoperative posturing requirement is difficult. Patients need to be informed of such concerns before surgery.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshBlood Transfusion, Autologousen_GB
dc.subject.meshCombined Modality Therapyen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshGases/*therapeutic useen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.mesh*Platelet Transfusionen_GB
dc.subject.meshPostoperative Perioden_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshRetinal Perforations/surgery/*therapyen_GB
dc.subject.meshTransforming Growth Factor beta/*therapeutic useen_GB
dc.subject.meshVisual Acuityen_GB
dc.subject.mesh*Vitrectomyen_GB
dc.titleSurgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.en_GB
dc.contributor.departmentDepartment of Ophthalmology, Cork University Hospital, Wilton, Ireland.en_GB
dc.identifier.journalThe British journal of ophthalmologyen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.